Larimar Therapeutics (LRMR) Interest Expenses (2013 - 2025)

Larimar Therapeutics' Interest Expenses history runs 13 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• Quarterly Interest Expenses fell 99.13% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (down 99.13% YoY) and the FY2025 annual result came in at $1.5 million, down 99.13% from the prior year.
• Interest Expenses was $1.5 million for Q4 2025 at Larimar Therapeutics, up from $1.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at $173.0 million in Q4 2024 and bottomed at $1.2 million in Q2 2025.
• A 5-year average of $33.0 million and a median of $7.3 million in 2023 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2021 — Interest Expenses surged 719.81% — and 2025, when it sank 99.13%.
• Larimar Therapeutics' Interest Expenses stood at $124.0 million in 2021, then rose by 5.5% to $130.8 million in 2022, then climbed by 8.36% to $141.8 million in 2023, then gained by 22.05% to $173.0 million in 2024, then sank by 99.13% to $1.5 million in 2025.
• Business Quant data shows LRMR's Interest Expenses at $1.5 million in Q4 2025, $1.2 million in Q3 2025, and $1.2 million in Q2 2025.